Hannah Valantine - 12 Nov 2025 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)

Role
Director
Signature
/s/ Will Solis, Attorney-in-Fact
Issuer symbol
BBIO
Transactions as of
12 Nov 2025
Net transactions value
-$449,028
Form type
4
Filing time
14 Nov 2025, 16:50:41 UTC
Previous filing
30 Jun 2025
Next filing
03 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Valantine Hannah Director C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR., SUITE 250, PALO ALTO /s/ Will Solis, Attorney-in-Fact 14 Nov 2025 0001855608

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BBIO Common Stock Options Exercise $1,234,700 +25,484 +341% $48.45 32,949 12 Nov 2025 Direct
transaction BBIO Common Stock Sale $1,683,728 -25,484 -77% $66.07 7,465 12 Nov 2025 Direct
holding BBIO Common Stock 398 12 Nov 2025 By Spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BBIO Stock Option (Right to Buy) Options Exercise $0 -25,484 -50% $0.000000 25,484 12 Nov 2025 Common Stock 25,484 $48.45 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vested and became exercisable in three annual installments after October 25, 2021.

Remarks:

Exhibit 24 - Power of Attorney